CARL L GORDON
CIK 1282930 · last filed 2026-01-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$260.72M
Companies
21
Total Filings
105
Lifetime Open-Market Net
$29.49M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| CMPX | Director | 15,219,994 | $2.04 | $31.05M | $14.98M | 10 | 2026-01-05 |
| KROS | Director | 764,405 | $10.07 | $7.70M | -$5.00M | 8 | 2025-12-18 |
| MBX | Director | 747,887 | $60.06 | $44.92M | $14.02M | 3 | 2025-02-19 |
| NCNA | Director | — | $1.29 | — | $0 | 1 | 2024-08-23 |
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | 1,968,480 | $52.95 | $104.23M | $17.44M | 9 | 2024-07-17 |
| ACET | Director | 41,154 | $8.20 | $337.5K | $9.33M | 10 | 2024-06-07 |
| Theseus Pharmaceuticals, Inc. (THRX) Delisted | Director | 0 | $4.06 | $0 | $14.49M | 9 | 2024-02-14 |
| AVBP | Director | 1,513,664 | $29.98 | $45.38M | $8.00M | 1 | 2024-01-31 |
| Kinnate Biopharma Inc. (KNTE) Delisted | Director | 1,368,339 | $2.65 | $3.63M | $24.75M | 9 | 2023-06-13 |
| Disc Medicine, Inc. (GMTX) Delisted | Director | — | $13.50 | — | $0 | 1 | 2021-10-06 |
| ORIC | Director | 2,212,571 | $11.91 | $26.35M | -$10.67M | 8 | 2021-06-17 |
| Prevail Therapeutics Inc. (PRVL) Delisted | Director | 13,822,463 | — | — | $15.00M | 2 | 2020-06-19 |
| Turning Point Therapeutics, Inc. (TPTX) Delisted | Director | 2,027,550 | $76.01 | $154.11M | $6.48M | 2 | 2020-06-17 |
| ALEC | Director | 94,075 | $1.52 | $143.0K | $7.82M | 2 | 2019-05-14 |
| ARMO BioSciences, Inc. (ARMO) Delisted | Director | 0 | — | — | $0 | 3 | 2018-06-22 |
| X4 Pharmaceuticals, Inc (ASNS) Delisted | Director | 3,115 | $0.08 | $243 | $5.00M | 4 | 2018-06-07 |
| NTLA | Director | 2,662,180 | $10.89 | $28.99M | $4.50M | 3 | 2017-05-19 |
| Cartesian Therapeutics, Inc. (SELB) Delisted | Director | 12,193 | $0.88 | $10.7K | $7.70M | 1 | 2016-06-29 |
| AMRN | Director | 285 | $13.95 | $4.0K | -$108.10M | 13 | 2012-09-05 |
| PCRX | Director | 2,828,941 | $26.81 | $75.84M | $3.75M | 1 | 2011-02-10 |
| GNOM | Director | — | $53.90 | — | $0 | 1 | 2010-12-02 |
Recent Filings · Page 3 of 11
105 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-01-26 | ACET | Buy (P) | +3,125,000 | $7.50M | EDGAR |
| 2023-08-16 | ACET | Mixed | — | $0 | EDGAR |
| 2023-07-19 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Buy (P) | +479,932 | $1.46M | EDGAR |
| 2023-06-29 | ACET | Buy (P) | +875,000 | $1.83M | EDGAR |
| 2023-06-14 | Terns Pharmaceuticals, Inc. (TERN) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-13 | Theseus Pharmaceuticals, Inc. (THRX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-13 | Kinnate Biopharma Inc. (KNTE) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-08 | KROS | Grant (A) | — | $0 | EDGAR |
| 2023-06-02 | ACET | Grant (A) | +5,900 | $0 | EDGAR |
| 2023-05-08 | Kinnate Biopharma Inc. (KNTE) Delisted | Buy (P) | +1,460,932 | $4.09M | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.